Program
ocankitug
Also written as “CM326”, “CM326(formulation 1)” and “CM326(formulation 2)”.
Its studies are mostly in Asthma · Nasal Polyps · Dermatitis, Atopic · Pulmonary Disease, Chronic Obstructive, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciences | 81 open or running | phase 2since Dec 13, 2021 | Apr 8, 2021 | none ahead |
| CSPC Pharmaceutical Group | 54 open or running | phase 3since Jan 11, 2026 | Mar 6, 2023 | Jul 1, 2027phase 2 · NCT07418736 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
CM326
, phase 3, as of Aug 20, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 8, 2021First study: phase 1 study in AsthmaNew to Keymed BiosciencesKeymed Biosciences · NCT04842201 · 44 enrolled · China
- Dec 9, 2021Phase 1 study in AsthmaKeymed Biosciences · NCT05171348 · 40 enrolled · China
- Dec 13, 2021Phase 2 study in Moderate-to-severe Atopic DermatitisKeymed Biosciences · NCT05186922 · 54 enrolled · China
- Mar 18, 2022Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsKeymed Biosciences · NCT05324137 · 88 enrolled · China
- Dec 26, 20222 phase 2 studiesKeymed Biosciences · NCT05671445, NCT05671432
- Jan 27, 2023Phase 1 study in HealthyKeymed Biosciences · NCT05715333 · 46 enrolled · China
- Mar 6, 2023CSPC Pharmaceutical Group's first study: phase 2 study in Moderate to Severe AsthmaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05774340 · 207 enrolled · China
- Apr 15, 2024Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsKeymed Biosciences · NCT06372678 · 90 planned · China
- Jan 11, 2026Phase 3 study in Moderate to Severe AsthmaPhase 3 reachedCSPC Pharmaceutical Group · NCT07372287 · 230 planned · China
- Feb 4, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT07418736 · 318 planned · China
- Feb 12, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsCSPC Pharmaceutical Group · NCT07420257 · 212 planned
- Apr 14, 2026Phase 1 study in Healthy SubjectsCSPC Pharmaceutical Group · NCT07560033 · 192 planned
Ahead
- Jul 1, 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT07418736
- Oct 30, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsCSPC Pharmaceutical Group · NCT07420257
- Dec 31, 2028Primary completion: phase 3 study in Moderate to Severe AsthmaCSPC Pharmaceutical Group · NCT07372287
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07560033Healthy Subjects | 1 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 1, 2026 | 192 |
| NCT07420257Chronic Rhinosinusitis With Nasal Polyps | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 30, 2028 | 212 |
| NCT07418736Pulmonary Disease, Chronic Obstructive · China | 2 | Recruiting | CSPC Pharmaceutical Group | Jul 1, 2027 | 318 |
| NCT07372287Moderate to Severe Asthma · China | 3 | Recruiting | CSPC Pharmaceutical Group | Dec 31, 2028 | 230 |
| NCT06372678Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Not yet recruiting | Keymed Biosciences | Jun 30, 2026 | 90 |
| NCT05774340Moderate to Severe Asthma · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Jan 2025 | 207 |
| NCT05715333Healthy · China | 1 | Completed | Keymed Biosciences | Oct 4, 2023 | 46 |
| NCT05671445Dermatitis, Atopic · China | 2 | UNKNOWN | Keymed Biosciences | Mar 28, 2024 | 100 |
| NCT05671432Moderate-to-severe Atopic Dermatitis · China | 2 | UNKNOWN | Keymed Biosciences | Dec 30, 2023 | 240 |
| NCT05324137Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Completed | Keymed Biosciences | Mar 29, 2024 | 88 |
| NCT05186922Moderate-to-severe Atopic Dermatitis · China | 2 | UNKNOWN | Keymed Biosciences | Jan 2023 | 54 |
| NCT05171348Asthma · China | 1 | Completed | Keymed Biosciences | Oct 11, 2022 | 40 |
| NCT04842201Asthma · China | 1 | Completed | Keymed Biosciences | Sep 28, 2021 | 44 |
How it is read
Names in the registry
- “CM326”, 10 entries
- “CM326(formulation 1)”, 1 entry
- “CM326(formulation 2)”, 1 entry
- “CM326 injection”, 1 entry
- “CM326 dose 1”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 4 studies
- Nasal Polyps, 3 studies
- Dermatitis, Atopic, 3 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.